Ketonemia
Methodology & AI Transparency ⓘ
Ketonemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Ketonemia (ICD-10-CM E88.89), Weight Management & Metabolic Syndrome protocols prioritize thyroid/cortisol exclusion [Ketonemia E88.89] paired with baseline and interval ALT & Fasting in Ketonemia (E88.89: Triglycerides) assessment.
- 2 Real-world patient consensus: Mapped to Weight Management & Metabolic Syndrome under ICD-10-CM E88.89 for Ketonemia clinical workups.
- 3 Typical cash cost range: Clinicians assessing Ketonemia focus on ectopic hepatic lipid in Ketonemia (E88.89: storage) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Ketonemia monitoring tracks ALT & Fasting in Ketonemia (E88.89: Triglycerides) toward ALT < 25 U/L; TG < 100 mg/dL (E88.89).
Ask our AI Specialists anything about Ketonemia
What Is Ketonemia?
For patients presenting with Ketonemia (ICD-10-CM E88.89), Weight Management & Metabolic Syndrome protocols prioritize thyroid/cortisol exclusion [Ketonemia E88.89] paired with baseline and interval ALT & Fasting in Ketonemia (E88.89: Triglycerides) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
In Ketonemia (E88.89), physiological disruption stems from ectopic hepatic lipid in Ketonemia (E88.89: storage), informing Weight Management & Metabolic Syndrome protocols that track DEXA Visceral Adipose in Ketonemia (E88.89: Tissue (VAT)) (< 1.0 lb (< 100 cm2) (E88.89)).
Common Symptoms & Clinical Signs
- • Presentation of Ketonemia (E88.89): joint load discomfort in Ketonemia (E88.89: in knees, hips,)
- • Secondary Ketonemia clinical sign: daytime sluggishness or in Ketonemia (E88.89: loud snoring linked)
- • Symptom flares in Ketonemia correlating with ALT & Fasting in Ketonemia (E88.89: Triglycerides) deviation outside ALT < 25 U/L; TG < 100 mg/dL (E88.89)
- • Functional weight & metabolism impact requiring thyroid/cortisol exclusion [Ketonemia E88.89] evaluation (E88.89)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ketonemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ALT & Fasting in Ketonemia (E88.89: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Ketonemia (E88.89: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Ketonemia E88.89] | < 0.50 (E88.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ketonemia
Treatment selection for Ketonemia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ketonemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1-based therapies and limb outcomes in: What a 240,000-Participant Study Found In real-world PAD populations, GLP-1-based therapies are associated with meaningful reductions in both limb and heart and blood vessel outcomes. Diabetes research and clinical practice • 2026-06-15 • Meta-Analysis | N = 240,000 | 94/100 | PMID 42009258 ↗ |
| New Insights on Effect of Subcutaneous Semaglutide vs Placebo as an add-on booster to Intensive: What a 611-Participant Study Found Of 611 randomized participants (495 women [81.0%], mean age 46 years [SD, 13], body weight 105.8 kg [SD, 22.9], and body mass index 38.0 [SD, 6.7]), 567 (92.8%) completed the trial, and 505 (82.7%) were receiving treatment at... JAMA • 2021-04-13 • Phase III Randomized Trial | N = 611 | 93/100 | PMID 33625476 ↗ |
| New Insights on Weight maintenance and additional weight loss with liraglutide after: What a 422-Participant Study Found Liraglutide, with diet and exercise, maintained weight loss achieved by caloric restriction and induced further weight loss over 56 weeks. International journal of obesity (2005) • 2013-11-15 • Randomized Controlled Trial | N = 422 | 93/100 | PMID 23812094 ↗ |
| What the Latest Evidence Really Says About GLP-1 Receptor/Dual Agonists for Weight Tirzepatide and Semaglutide_SC are most effective for clinically meaningful weight loss. Diabetes, obesity & metabolism • 2026-06-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41872986 ↗ |
| What the Latest Evidence Really Says About Meta-analysis of the real-world benefits and safety of pharmacological treatments Tirzepatide was effective in full symptom relief of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis. Nature medicine • 2025-10-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41039116 ↗ |
Ketonemia Patient Community & “People Like Me” Threads
Filter Ketonemia community threads and patient logs by age, biological sex, dosage, and treatment duration.